New Generational Research Peptide
The Retatrutide (AQ pen) offers a sterile, pre-mixed solution in a dial-a-dose pen. Triple agonist action (GLP-1 / GIP / Glucagon) for advanced research applications.
Technical Specifications
Designed for precise titration in research protocols. The transparent window allows for easy monitoring of remaining volume.
- Concentration --- 30 mg / 3 ml
- Dosing Increment --- 1 Click = 0.1 mg
- Total Capacity --- 300 clicks (30 mg)
- Purity --- >99.0% (HPLC)
- Endotoxins ---- < 0.003 EU/mg
- Research Titration Protocol
Suggested starting protocol: 0.5 mg weekly. Increase by 0.5 mg every 4 weeks up to 2.5 mg, as tolerated by the subject.
Research Without Boundaries
Retatrutide represents the next evolution in peptide research. Engineered for precision, consistency, and advanced metabolic exploration. As a triple-pathway GLP-1, GIP, and glucagon receptor agonist, it is designed for researchers seeking a streamlined, high-purity solution without unnecessary complexity.
Each pre-filled aqueous pen is manufactured for accuracy and ease of use, eliminating reconstitution while maintaining strict quality controls. Cold-shipped and stability-tested, this formulation supports reliable handling across controlled environments and travel conditions.
From purity standards to tamper-evident packaging, every detail reflects a commitment to dependable research materials built for serious investigation, not shortcuts.
- Triple-pathway peptide design (GLP-1, GIP, glucagon)
- Pre-filled aqueous delivery—no mixing required
- High-purity, QC-verified formulation
- Cold-chain compliant with short-term room-temperature stability
- Sterilized, tamper-evident pen system
Why Take Retatrutide?
Retatrutide is a peptide drug designed to act on three hormone receptors in the body:
- GLP-1 (glucagon-like peptide-1)
- GIP (glucose-dependent insulinotropic polypeptide)
- Glucagon receptors
This “triple-agonist” approach may enhance appetite control, energy use, and blood sugar regulation more effectively than older drugs that target only one or two pathways
Main Benefits
Retatrutide is a peptide drug designed to act on three hormone receptors in the body:
1. Substantial Weight Loss
Clinical studies have shown that retatrutide can produce dramatic weight loss in adults with obesity or overweight:
- Participants lost an average of ~17–24% of their body weight over ~48 weeks in clinical trials.
2. Appetite Suppression and Metabolic Effects
Retatrutide may:
- Reduce hunger and food intake
- Slow gastric emptying (making people feel full sooner)
- Potentially increase calorie burning by influencing metabolism
This helps with both weight loss and behavioral eating changes
3. Improvements in Metabolic Health
Beyond weight loss, retatrutide has shown promise in improving:
- Blood sugar control, which is beneficial for people with type 2 diabetes or prediabetes
- Cardiometabolic risk markers, which may help reduce the risk of heart disease and related conditions (still under study).
Retatrutide ZPHC (AQ pen) 30 mg Premixed Pen
Retatrutide — triple GLP-1 / GIP / glucagon receptor agonist
30 mg pre-filled aqueous pen • 300 clicks × 0.1 mg
- No mixing required: sterile water-based solution delivered via precision dial-a-dose pen.
- Powerful weight-loss synergy: GLP-1, GIP and glucagon receptor activation enhances satiety, slows gastric emptying, improves insulin sensitivity and increases energy expenditure.
- Suggested research titration: 0.5 mg weekly → increase by 0.5 mg every 4 weeks up to 2.5 mg, as tolerated.
- Each click = 0.1 mg: transparent window shows remaining volume; full pen supplies 300 clicks.
- Storage: ship cold; refrigerate 2 – 8 °C once opened; stable 30 days at 25 °C for travel.
- QC: ≥ 99 % purity, endotoxin < 0.03 EU/mg; pen sterilised & tamper-evident.
$449.00 USD
Pickup currently not available